(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 6.09% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Amneal Pharmaceuticals's revenue in 2026 is $3,117,548,000.On average, 8 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,016,503,524,177, with the lowest AMRX revenue forecast at $960,935,942,271, and the highest AMRX revenue forecast at $1,065,684,027,703. On average, 8 Wall Street analysts forecast AMRX's revenue for 2027 to be $1,100,493,604,874, with the lowest AMRX revenue forecast at $1,043,329,253,373, and the highest AMRX revenue forecast at $1,153,825,709,347.
In 2028, AMRX is forecast to generate $1,189,593,348,275 in revenue, with the lowest revenue forecast at $1,122,209,671,366 and the highest revenue forecast at $1,252,506,070,318.